CoChat

Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety

Open access
Müllertz, Alberte Laura Oest, Sandsdal, Rasmus Michael, Jensen, Simon Birk Kjær, Torekov, Signe Sørensen · 2024 · Obesity Reviews
Cited by 46

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Summary: Potent incretin‐based therapy shows promise for the treatment of obesity along with reduced incidence of cardiovascular events in patients with preexisting cardiovascular disease and obesity. This study assessed the efficacy and safety of the incretin‐based obesity treatments, once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes. Of the 744 records identified, seven randomized controlled trials (n = 5140) were included. Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide. The treatment effect, shown as placebo‐subtracted difference, on body weight was −15.0% (95% CI, −17.8 to −12.2) with −12.9% (95% CI, −14.7 to −11.1) for semaglutide and −19.2% (95% CI, −22.2 to −16.2) for tirzepatide. The treatment effect on waist circumference was −11.4 cm (95% CI, −13.7 to −9.2) with −9.7 cm (95% CI, −10.8 to −8.5) for semaglutide and −14.6 cm (95% CI, −15.8 to −13.4) for tirzepatide. The adverse events related to semaglutide and tirzepatide were primarily of mild‐to‐moderate severity and mostly gastrointestinal, which was more frequent during the dose‐titration period and leveled off during the treatment period. This emphasizes that once‐weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg induce large reductions in body weight and waist circumference and are generally well‐tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/obr.13717

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 22

  1. 10.1186/s12889‐021‐12449‐2 · DOI · Paper page
  2. 10.1093/humrep/deac096 · DOI
  3. 10.1038/s41366‐021‐00788‐4 · DOI · Paper page
  4. 10.1503/cmaj.191707 · DOI · Paper page
  5. 10.1093/tbm/ibab110 · DOI
  6. 10.1038/s41467‐022‐32307‐y · DOI · Paper page
  7. 10.1093/jn/nxz296 · DOI · Paper page
  8. 10.1007/s40264‐019‐00812‐7 · DOI
  9. 10.4314/ahs.v19i3.35 · DOI · Paper page
  10. 10.1016/S0140‐6736(18)31773‐2 · DOI · Paper page
  11. 10.1080/00325481.2022.2147326 · DOI · Paper page
  12. 10.1016/s0140‐6736(21)01324‐6 · DOI · Paper page
  13. 10.1002/oby.23612 · DOI
  14. 10.15605/jafes.037.02.14 · DOI
  15. 10.1038/s41591‐022‐02026‐4 · DOI · Paper page
  16. 10.1371/journal.pone.0285197 · DOI · Paper page
  17. 10.1002/9781119536604 · DOI · Paper page
  18. Veritas Health Innovation.Covidence systematic review software. Accessed November 22 2023.www.covidence.org
  19. Cochrane Training. Review Manager (RevMan). Accessed November 22 2023.https://training.cochrane.org/online‐learning/core‐software/revman
  20. 10.1001/jama.2021.3224 · DOI · Paper page
  21. 10.1038/oby.2012.70 · DOI
  22. 10.1056/nejmoa066254 · DOI · Paper page

Cited by

See all 46

Metadata

Authors
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S.
Venue
Obesity Reviews
Publisher
Wiley
Published
2024-03-11
Volume
25
Issue
5
Pages
e13717-e13717
ISSN
  • 1467-7881 (ISSN-L)
  • 1467-789X
OpenAlex
W4392658789
Cited by
46
References
47
FWCI
4.62
Type
journal article
Language
en
Open access
hybrid
Funders
  • Helsefonden (20‐B‐0389)
  • Novo Nordisk Fonden (NNF22SA0079901, NNF16OC0019968, NNF15CC0018486, NNF23OC0084305)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. https://app.cochat.ai/papers/10.1111/obr.13717
The paper
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024). Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obesity Reviews. https://doi.org/10.1111/obr.13717

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.